Cited by Chronic Disease Modeling

Global burden of metabolic diseases, 1990–2021 DOI

Huai Zhang, Xiaodong Zhou, Michael D. Shapiro

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 160, P. 155999 - 155999

Published: Aug. 14, 2024

Language: Английский

Citations

Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies DOI

Kai En Chan,

Elden Yen Hng Ong,

Charlotte Hui Chung

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 22(3), P. 488 - 498.e14

Published: Sept. 28, 2023

Language: Английский

Citations

Global burden of cardiovascular diseases: projections from 2025 to 2050 DOI

Bryan Chong,

Jayanth Jayabaskaran,

Silingga Metta Jauhari

et al.

European Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 13, 2024

Abstract Aims The prediction of future trends in cardiovascular disease (CVD) mortality and their risk factors can assist policy-makers healthcare planning. This study aims to project geospatial CVDs underlying from 2025 2050. Methods results Using historical data on disability-adjusted life years (DALYs) the Global Burden Disease (GBD) 2019 study, encompassing period 1990 2019, Poisson regression was performed model DALYs associated with CVD its Subgroup analysis based GBD super-regions. Between 2050, a 90.0% increase prevalence, 73.4% crude mortality, 54.7% are projected, an expected 35.6 million deaths 2050 (from 20.5 2025). However, age-standardized prevalence will be relatively constant (−3.6%), decreasing (−30.5%) (−29.6%). In ischaemic heart remain leading cause (20 deaths) while high systolic blood pressure main factor driving (18.9 deaths). Central Europe, Eastern Asia super-region is set incur highest rate (305 per 100 000 population). Conclusion coming decades, global suggests that net effect summative preventative efforts likely continue unchanged. fall reflects improvement medical care following diagnosis. systems expect rapid rise driven by ageing populace. continued burden largely attributed atherosclerotic diseases. Registration Not applicable.

Language: Английский

Citations

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies DOI

Michail Kokkorakis, Emir Muzurović, Špela Volčanšek

et al.

Pharmacological Reviews, Journal Year: 2024, Volume and Issue: 76(3), P. 454 - 499

Published: Jan. 30, 2024

Steatotic liver disease (SLD) displays a dynamic and complex phenotype. Consequently, the metabolic dysfunction-associated steatotic (MASLD)/metabolic steatohepatitis (MASH) therapeutic pipeline is expanding rapidly in multiple directions. In parallel, non-invasive tools for diagnosing monitoring responses to interventions are being studied, clinically feasible findings explored as primary outcomes interventional trials. The realization that distinct subgroups exist under umbrella of SLD should guide more precise personalized treatment recommendations facilitate advancements pharmacotherapeutics. This review summarizes recent updates pathophysiology-based nomenclature outlines both effective pharmacotherapeutics those MASLD/MASH, detailing their mode action current status phase 2 3 clinical Of extensive arsenal MASLD/MASH pipeline, several have been rejected, whereas other, mainly monotherapy options, shown only marginal benefits now tested part combination therapies, yet others still development monotherapies. Although successful drug candidate (or combinations) remains elusive, such approaches will ideally target MASH fibrosis while improving cardiometabolic risk factors. Due urgent need novel strategies potential availability safety tolerability data, repurposing existing approved drugs an appealing option. Finally, it essential highlight and, by extension, MASLD be recognized approached systemic affecting organs, with vigorous implementation interdisciplinary coordinated plans. Significance Statement SLD, including, among others, MASH, considered most prevalent chronic condition than one-fourth global population. aims provide information regarding pathophysiology, diagnosis, management line guidelines Collectively, hoped provided furthers understanding state direct implications stimulates additional research initiatives.

Language: Английский

Citations

Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 DOI

Pojsakorn Danpanichkul,

Kanokphong Suparan,

Priyata Dutta

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 158, P. 155958 - 155958

Published: June 26, 2024

Language: Английский

Citations

Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019 DOI

Pojsakorn Danpanichkul, Majd B. Aboona,

Banthoon Sukphutanan

et al.

Hepatology, Journal Year: 2024, Volume and Issue: 80(4), P. 828 - 843

Published: April 8, 2024

The worldwide burden of cancer is increasing in younger populations. However, the epidemiology primary liver remains understudied young adults compared to other forms.

Language: Английский

Citations

Obesity and dyslipidemia in early life: Impact on cardiometabolic risk DOI

Aleksandra Zeljković, Jelena Vekić,

Aleksandra Stefanovic

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 156, P. 155919 - 155919

Published: April 21, 2024

Language: Английский

Citations

Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis DOI

Bryan C. Tan,

Xin‐Hui Pan,

Han Shi Jocelyn Chew

et al.

International Journal of Obesity, Journal Year: 2023, Volume and Issue: 47(8), P. 677 - 685

Published: May 31, 2023

Language: Английский

Citations

Epicardial Adipose Tissue Assessed by Computed Tomography and Echocardiography Are Associated With Adverse Cardiovascular Outcomes: A Systematic Review and Meta-Analysis DOI

Bryan Chong,

Jayanth Jayabaskaran,

Jitesh Ruban

et al.

Circulation Cardiovascular Imaging, Journal Year: 2023, Volume and Issue: 16(5)

Published: May 1, 2023

Epicardial adipose tissue (EAT) has garnered attention as a prognostic and risk stratification factor for cardiovascular disease. This study, via meta-analyses, evaluates the associations between EAT outcomes stratified across imaging modalities, ethnic groups, study protocols.Medline Embase databases were searched without date restriction on May 2022 articles that examined outcomes. The inclusion criteria (1) studies measuring of adult patients at baseline (2) reporting follow-up data interest. primary outcome was major adverse events. Secondary included cardiac death, myocardial infarction, coronary revascularization, atrial fibrillation.Twenty-nine published 2012 2022, comprising 19 709 patients, in our analysis. Increased thickness volume associated with higher risks death (odds ratio, 2.53 [95% CI, 1.17-5.44]; P=0.020; n=4), infarction 2.63 1.39-4.96]; P=0.003; n=5), revascularization 2.99 1.64-5.44]; P<0.001; fibrillation (adjusted odds 4.04 3.06-5.32]; n=3). For 1 unit increment continuous measure EAT, computed tomography volumetric quantification hazard 1.74 1.42-2.13]; P<0.001) echocardiographic 1.20 1.09-1.32]; conferred an increased events.The utility biomarker predicting prognosticating disease is promising, being identified independent predictors events.URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42022338075.

Language: Английский

Citations

The burden of cardiovascular disease in Asia from 2025 to 2050: a forecast analysis for East Asia, South Asia, South-East Asia, Central Asia, and high-income Asia Pacific regions DOI

Rachel Sze Jen Goh,

Bryan Chong,

Jayanth Jayabaskaran

et al.

The Lancet Regional Health - Western Pacific, Journal Year: 2024, Volume and Issue: 49, P. 101138 - 101138

Published: July 10, 2024

Given the rapidly growing burden of cardiovascular disease (CVD) in Asia, this study forecasts CVD and associated risk factors Asia from 2025 to 2050.

Language: Английский

Citations